FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2804992303> ?p ?o ?g. }

• W2804992303 abstract "The VeriStrat test is a serum proteomic signature originally discovered in non-responders to second line gefitinib treatment and subsequently used to predict differential benefit from erlotinib versus chemotherapy in previously treated advanced non-small cell lung cancer (NSCLC). Multiple studies highlight the clinical utility of the VeriStrat test, however, the mechanistic connection between VeriStrat-poor classification and poor prognosis in untreated and previously treated patients is still an active area of research. The aim of this study was to correlate VeriStrat status with other circulating biomarkers in advanced NSCLC patients – each with respect to clinical outcomes. Serum samples were prospectively collected from 57 patients receiving salvage chemotherapy and 70 non-EGFR mutated patients receiving erlotinib. Patients were classified as either VeriStrat good or poor based on the VeriStrat test. Luminex immunoassays were used to measure circulating levels of 102 distinct biomarkers implicated in tumor aggressiveness and treatment resistance. A Cox PH model was used to evaluate associations between biomarker levels and clinical outcome, whereas the association of VeriStrat classifications with biomarker levels was assessed via the Mann-Whitney Rank Sum test. VeriStrat was prognostic for outcome within the erlotinib treated patients (HR = 0.29, p < 0.0001) and predictive of differential treatment benefit between erlotinib and chemotherapy ((interaction HR = 0.25; interaction p = 0.0035). A total of 27 biomarkers out of 102 unique analytes were found to be significantly associated with OS (Cox PH p ≤ 0.05), whereas 16 biomarkers were found to be associated with PFS. Thrombospondin-2, C-reactive protein, TNF-receptor I, and placental growth factor were the analytes most highly associated with OS, all with Cox PH p-values ≤0.0001. VeriStrat status was found to be significantly associated with 23 circulating biomarkers (Mann-Whitney Rank Sum p ≤ 0.05), 6 of which had p < 0.001, including C-reactive protein, IL-6, serum amyloid A, CYFRA 21.1, IGF-II, osteopontin, and ferritin. Strong associations were observed between survival and VeriStrat classifications as well as select circulating biomarkers associated with fibrosis, inflammation, and acute phase reactants as part of this study. The associations between these biomarkers and VeriStrat classification might have therapeutic implications for poor prognosis NSCLC patients, particularly with new immunotherapeutic treatment options." @default.
• W2804992303 created "2018-06-01" @default.
• W2804992303 creator A5008913834 @default.
• W2804992303 creator A5024343309 @default.
• W2804992303 creator A5029075855 @default.
• W2804992303 creator A5032871452 @default.
• W2804992303 creator A5040798556 @default.
• W2804992303 creator A5043971397 @default.
• W2804992303 creator A5053344068 @default.
• W2804992303 creator A5070454355 @default.
• W2804992303 creator A5076167727 @default.
• W2804992303 creator A5085048939 @default.
• W2804992303 date "2018-03-20" @default.
• W2804992303 modified "2023-09-26" @default.
• W2804992303 title "The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients" @default.
• W2804992303 cites W1970191747 @default.
• W2804992303 cites W1984031404 @default.
• W2804992303 cites W1986187845 @default.
• W2804992303 cites W1986229463 @default.
• W2804992303 cites W1994993231 @default.
• W2804992303 cites W2003521979 @default.
• W2804992303 cites W2004633979 @default.
• W2804992303 cites W2006835408 @default.
• W2804992303 cites W2051096017 @default.
• W2804992303 cites W2073347045 @default.
• W2804992303 cites W2075840772 @default.
• W2804992303 cites W2089899771 @default.
• W2804992303 cites W2094661168 @default.
• W2804992303 cites W2099408048 @default.
• W2804992303 cites W2117692326 @default.
• W2804992303 cites W2131687087 @default.
• W2804992303 cites W2134213739 @default.
• W2804992303 cites W2154589460 @default.
• W2804992303 cites W2155478415 @default.
• W2804992303 cites W2278001291 @default.
• W2804992303 cites W2296148183 @default.
• W2804992303 cites W2317184793 @default.
• W2804992303 cites W2411767313 @default.
• W2804992303 cites W2488012409 @default.
• W2804992303 cites W2559419371 @default.
• W2804992303 cites W2560764769 @default.
• W2804992303 cites W2569392536 @default.
• W2804992303 cites W2570923585 @default.
• W2804992303 cites W2587771387 @default.
• W2804992303 cites W2603105315 @default.
• W2804992303 cites W2607591686 @default.
• W2804992303 cites W3000658234 @default.
• W2804992303 doi "https://doi.org/10.1186/s12885-018-4193-0" @default.
• W2804992303 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5861613" @default.
• W2804992303 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29558888" @default.
• W2804992303 hasPublicationYear "2018" @default.
• W2804992303 type Work @default.
• W2804992303 sameAs 2804992303 @default.
• W2804992303 citedByCount "29" @default.
• W2804992303 countsByYear W28049923032018 @default.
• W2804992303 countsByYear W28049923032019 @default.
• W2804992303 countsByYear W28049923032020 @default.
• W2804992303 countsByYear W28049923032021 @default.
• W2804992303 countsByYear W28049923032022 @default.
• W2804992303 crossrefType "journal-article" @default.
• W2804992303 hasAuthorship W2804992303A5008913834 @default.
• W2804992303 hasAuthorship W2804992303A5024343309 @default.
• W2804992303 hasAuthorship W2804992303A5029075855 @default.
• W2804992303 hasAuthorship W2804992303A5032871452 @default.
• W2804992303 hasAuthorship W2804992303A5040798556 @default.
• W2804992303 hasAuthorship W2804992303A5043971397 @default.
• W2804992303 hasAuthorship W2804992303A5053344068 @default.
• W2804992303 hasAuthorship W2804992303A5070454355 @default.
• W2804992303 hasAuthorship W2804992303A5076167727 @default.
• W2804992303 hasAuthorship W2804992303A5085048939 @default.
• W2804992303 hasBestOaLocation W28049923031 @default.
• W2804992303 hasConcept C121608353 @default.
• W2804992303 hasConcept C126322002 @default.
• W2804992303 hasConcept C143998085 @default.
• W2804992303 hasConcept C185592680 @default.
• W2804992303 hasConcept C2776256026 @default.
• W2804992303 hasConcept C2776694085 @default.
• W2804992303 hasConcept C2778087573 @default.
• W2804992303 hasConcept C2779438470 @default.
• W2804992303 hasConcept C2780140570 @default.
• W2804992303 hasConcept C2780580887 @default.
• W2804992303 hasConcept C2781197716 @default.
• W2804992303 hasConcept C50382708 @default.
• W2804992303 hasConcept C55493867 @default.
• W2804992303 hasConcept C71924100 @default.
• W2804992303 hasConceptScore W2804992303C121608353 @default.
• W2804992303 hasConceptScore W2804992303C126322002 @default.
• W2804992303 hasConceptScore W2804992303C143998085 @default.
• W2804992303 hasConceptScore W2804992303C185592680 @default.
• W2804992303 hasConceptScore W2804992303C2776256026 @default.
• W2804992303 hasConceptScore W2804992303C2776694085 @default.
• W2804992303 hasConceptScore W2804992303C2778087573 @default.
• W2804992303 hasConceptScore W2804992303C2779438470 @default.
• W2804992303 hasConceptScore W2804992303C2780140570 @default.
• W2804992303 hasConceptScore W2804992303C2780580887 @default.
• W2804992303 hasConceptScore W2804992303C2781197716 @default.
• W2804992303 hasConceptScore W2804992303C50382708 @default.
• W2804992303 hasConceptScore W2804992303C55493867 @default.
• W2804992303 hasConceptScore W2804992303C71924100 @default.
• W2804992303 hasFunder F4320307056 @default.

• next